Login to Your Account



'Acadia' Think It Really Works? After Two Fails, Phase III Win

By Randy Osborne
Staff Writer

Tuesday, November 27, 2012

Two strikes – and investor suspense – led up to a home run for Acadia Pharmaceuticals Inc., which tweaked the designs of previous, failed Phase III trials and thereby met all endpoints in the latest one with pimavanserin in Parkinson's disease psychosis.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription